Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.
By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...
Combriax demonstrates strong immunogenicity across age groups, exceeding comparator vaccines for multiple influenza strains ...
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on ...
Moderna Inc. said it would ask U.S. and European regulators Monday to allow emergency use of its COVID-19 vaccine as new study results confirm the vaccine offers strong protection — ramping up the ...
COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s ...
You mentioned in a recent column that prospective randomized controlled trials (RCTs) are a powerful type of study. Can you ...
The world’s first combination seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has received marketing ...
The company posted $389 million in first-quarter revenue, well above analyst expectations, with 80% coming from international ...
Moderna (MRNA) stock jumps after Q1 2026 earnings beat on strong international COVID vaccine sales, despite wider loss driven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results